Xeris Biopharma Holdings, Inc.
NMS: XERSLive Quote
About Xeris Biopharma Holdings, Inc.
Healthcare
Biotechnology
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
📊 Fundamental Analysis
Xeris Biopharma Holdings, Inc. demonstrates a profit margin of 0.2%, which is below the sector average, suggesting competitive pressure.
The company recently reported 42.8% revenue growth, which is well above average for the Healthcare sector.
At a current price of $5.85, XERS currently sits at the 31st percentile of its 52-week range (Range: $3.95 - $10.08).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$1.06B
Trailing P/E
inf
Forward P/E
15.79
Beta (5Y)
0.99
52W High
$10.08
52W Low
$3.95
Avg Volume
1.83M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App